Search

A recent study conducted at Sohag University in Egypt has reported a rare case of neurofibromatosis type 1 (NF1) in a 2.5-year-old Egyptian child. The child presented with multiple congenital anomalies, including bilateral congenital glaucoma, giant congenital melanocytic nevi, alopecia, and hypospadias. The researchers identified a heterozygous missense variant in the NF1 gene through whole exome sequencing. This case highlights the importance of considering NF1 in newborns with congenital glaucoma, giant melanocytic nevi, scalp alopecia, and hypospadias, as these anomalies may be the first presenting features of the disorder. [Extracted from the article]

A study conducted by researchers at Sun Yat-sen University in Guangzhou, China, explores the use of an extended vertical lower trapezius island myocutaneous flap (eTIMF) for reconstructing soft tissue defects in patients with neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas. The researchers successfully used the eTIMF technique to repair substantial defects and remodel facial aesthetic units in patients with NF1. The procedure resulted in improved appearance, function, and quality of life for the patients. The study concludes that eTIMF is a safe, efficient, and simple technique for reconstructive surgery in NF1 patients. [Extracted from the article]

A new study conducted by researchers at the European Cancer Stem Cell Research Institute has provided insights into neurofibromatosis type 1 (NF1), a condition characterized by multiple Cafe au Lait Macules (CALMs). The study found that CALMs in NF1 are associated with biallelic NF1 loss, leading to activation of the Ras/mitogen-activated protein kinase (Ras/MAPK) and Wnt pathways. Additionally, reduced expression of the tumor suppressor pigment epithelium-derived factor (PEDF) was observed, resulting in increased melanocyte proliferation, migration, and invasion. The study also identified activation of the PI3K/AKT pathway in classical NF1 and NF1 melanoma, which may facilitate tumor growth. [Extracted from the article]

A recent study conducted at University Hospital Principe Asturias in Madrid, Spain, has found that the criteria for diagnosing neurofibromatosis type 1 (NF1) in young children is not sensitive enough. The study focused on a case of a girl with isolated café-au-lait spots, whose father had been diagnosed with NF1. However, both the girl and her father were found to have different de novo mutations in the NF1 gene. The researchers concluded that this finding has significant implications for the diagnostic process and genetic counseling. The study has been peer-reviewed and published in Pediatric Dermatology. [Extracted from the article]

A recent report from the National Institute of Child Health in Karachi, Pakistan discusses neurofibromatosis type 1 (NF1), an autosomal dominant disorder caused by a mutation in the NF1 gene. This mutation leads to the growth of tumors on nerves and can result in various systemic abnormalities, including skin changes, bone and eye abnormalities, hormonal imbalances, and complications with puberty. The report presents case studies of two patients with NF1 who experienced dichotomous variations in pubertal development. The researchers emphasize the importance of identifying the cause of precocious and delayed puberty in order to establish early treatment plans and reduce complications. [Extracted from the article]

A new report from Zhejiang University in China discusses research findings on neurofibromatosis type 1 (NF1), a nervous system disorder. The study aimed to investigate the clinical and genetic features of NF1 in Chinese families. Through genetic analysis, the researchers identified nine different NF1 variants in 10 unrelated Chinese families, including two novel variants. The study expands the understanding of the genetic spectrum of NF1 in the Chinese population. [Extracted from the article]

A recent report discusses research on neurofibromatosis type 1 (NF1), an autosomal dominant disorder caused by mutations in the NF1 gene. The study focused on the effects of cold atmospheric plasma (CAP) on NF1-associated peripheral nerve sheath tumors (PNSTs). The researchers found that NF1-associated PNSTs were highly sensitive to CAP exposure, resulting in cell death. This study provides a unique opportunity to study the complex biology of NF1-associated tumors and offers potential for more effective therapies for these aggressive malignancies. [Extracted from the article]

A recent study conducted in Sao Paulo, Brazil, aimed to determine the prevalence of neurofibromatosis type 1 (NF1) in patients with neurofibromas of the eyelid and orbit. The researchers analyzed data from patients with pathology reports of neurofibroma from 2007 to 2022 and found that the prevalence of NF1 in this population was 47.62%. They concluded that patients with plexiform neurofibromas and those presenting with Lisch nodules should be investigated for NF1, and ophthalmological evaluation is crucial for identifying Lisch nodules. The study suggests that the family members of patients with these presentations should also be clinically and genetically tested if necessary. [Extracted from the article]

A recent study conducted at the King Hussein Cancer Center has reported a rare case of a malignant peripheral nerve sheath tumor (MPNST) in the thyroid of a patient with neurofibromatosis type 1 (NF1). MPNSTs are aggressive soft tissue sarcomas that typically arise from peripheral nerves and can be challenging to diagnose and treat. The case highlights the importance of screening MPNST patients for NF1 and vice versa, and emphasizes the expanding role of FDG PET/CT in comprehensive evaluations. This is the first reported case of NF1-associated MPNST with thyroid involvement worldwide. [Extracted from the article]

A recent study conducted by Sanford Research in Sioux Falls, South Dakota, has found that cognitive and motor impairment is common among individuals with neurofibromatosis type 1 (NF1), a tumor-predisposition disorder. The researchers used an NF1(+/ex42del) miniswine model to evaluate the mechanisms and characteristics of these impairments, as miniswine have anatomy and physiology more similar to humans. The study revealed abnormalities in certain brain regions, imbalances in neurotransmitters, and motor dysfunction in the miniswine model, which closely resemble the cognitive and motor impairments observed in NF1 patients. These findings suggest that the miniswine model can be a valuable resource for studying and developing potential therapeutic interventions for NF1-associated impairments. [Extracted from the article]

A recent study conducted by researchers at the University of Alabama at Birmingham has examined the effects of selumetinib treatment on neurofibromatosis type 1 (NF1). NF1 is a genetic disorder characterized by the development of skin lesions called cutaneous neurofibromas (cNFs). The study analyzed the transcriptome of cNF tumors before and during selumetinib treatment, identifying distinct populations of cells and evaluating differential gene expression. The findings suggest that there are significant changes in cell states, intercellular signaling, and extracellular matrix pathways following treatment, which could provide insights into treatment outcomes and inform future therapies. [Extracted from the article]

A recent report discusses research on neurofibromatosis type 1 (NF1), a genetic disorder characterized by mutations in the neurofibromin 1 gene. The research focuses on understanding the complex pathophysiology of NF1, which involves dysregulation of the RAS-MAPK signaling pathway. The study analyzes single-cell RNA sequencing data from human patients with NF1 tumors and investigates the role of cell-to-cell interactions and extracellular matrix (ECM) components in tumor development. The findings suggest potential therapeutic targets related to ECM and signaling pathways. Further experiments and analyses are ongoing. [Extracted from the article]

A study conducted by the Children's Hospital Capital Institute of Pediatrics in Beijing, China, has generated a human induced pluripotent stem cell (iPSC) line from a pediatric patient with neurofibromatosis type 1 (NF1) and epilepsy. The iPSC line exhibits pluripotency markers, maintains the NF1 gene mutation, and has the potential to differentiate into three germ layers. This iPSC line will be a valuable resource for investigating the underlying mechanisms and conducting drug screening related to NF1 and NF1-associated epilepsy. [Extracted from the article]

A recent study investigated the impact of pathogenic variants in the Ras-MAPK pathway on major white matter tracts in the human brain. The study focused on two genetic conditions, Noonan syndrome (NS) and Neurofibromatosis type-1 (NF1), which are both associated with hyperactivation of the Ras pathway and a high prevalence of neuropsychiatric disorders. Diffusion-weighted imaging data was collected from children with NS, NF1, and a control group, and the results showed that both NS and NF1 exhibited reduced white matter integrity compared to controls. However, NS had a more extensive effect on white matter integrity, particularly in association tracts, while NF1 had specific effects on the corpus callosum. These findings suggest potential targets for brain-focused outcome measures in the treatment of these conditions. [Extracted from the article]

A recent study conducted by researchers at the University of the Witwatersrand in Johannesburg, South Africa, focused on neurofibromatosis type 1 (NF1), a genetic condition characterized by various symptoms such as cafe-au-lait macules, skin freckling, optic gliomas, and tumor predisposition. The study screened 26 unrelated Southern African patients suspected of having NF1 using next-generation sequencing and multiple ligation-dependent probe amplification (MLPA) analysis. The researchers identified causative variants in 58% of the patients, with 80% having single nucleotide variants (SNVs) and 20% having gene deletions. The study also found that Southern African patients with NF1 had a lower frequency of plexiform neurofibromas and a higher frequency of developmental/intellectual disability compared to other cohorts. The research offers a potential molecular testing strategy for diagnosing NF1 in low-resource environments. [Extracted from the article]

A recent report from High Point University in North Carolina discusses the potential use of silver nanoparticles (AgNPs) in the treatment of neurofibromatosis type 1 (NF1)-associated plexiform neurofibroma (pNF) cells. NF1 is a neurogenic condition characterized by mutations in the neurofibromin gene, which can lead to the development of pNFs. The researchers found that AgNPs were selectively cytotoxic to pNF cells compared to patient-matched Schwann cells. This suggests that AgNPs could be a promising approach for managing NF1-associated pNFs. Further research is needed to explore this potential treatment option. [Extracted from the article]

A recent study conducted by Yale University School of Medicine examined chronic pain in individuals with Neurofibromatosis Type 1 (NF1), a genetic disorder. The study used the Neurofibromatosis Pain Module (NFPM) to assess the impact of chronic pain on individuals with NF1. The results showed that participants reported moderate pain severity and that their daily lives and sleep were significantly affected by the pain. The study highlights the need for further research and effective treatments for chronic pain in individuals with NF1. [Extracted from the article]

A new report from Rutgers University New Jersey Medical School provides insights into the relationship between scoliosis and neurofibromatosis type 1 (NF1). NF1 is a common neurocutaneous syndrome in the United States, affecting 1 in 3000 individuals. The study found that scoliosis, a curvature of the spine, is the most common skeletal abnormality in NF1 patients, occurring in 10-30% of cases. The research analyzed data from the 2017 US National Inpatient Sample database and found that NF1 patients with scoliosis were typically younger, female, and white. They were also more likely to develop certain brain neoplasms and disorders, but less likely to develop certain pulmonary and cardiac complications. [Extracted from the article]

A recent study conducted by researchers at Tunis El Manar University provides updated information on neurofibromatosis type 1, a genetic disorder that causes the formation of benign tumors called neurofibromas. The study focuses on a case report of a 20-year-old North African female patient with neurofibromatosis type 1 who presented with a growing mass in her right gluteal region, later diagnosed as a giant cutaneous neurofibroma. Imaging studies revealed infiltration in several regions, including the urinary bladder wall, resulting in significant bilateral hydronephrosis. The researchers emphasize the importance of closely monitoring patients with neurofibromatosis type 1 for early detection of neurofibromas and prompt surgical intervention to prevent complications. [Extracted from the article]

A recent report from the Post Graduate Institute discusses neurofibromatosis type 1 (NF1), a neuro-cutaneous disorder with a wide range of manifestations. The researchers conducted a study on 29 individuals who met the clinical criteria for NF1 and found that 25 of them had pathogenic or likely pathogenic variants in the NF1 gene. They identified both known and novel variants, including deletions, nonsense, splice-site, missense, and duplications. The study highlights the importance of molecular testing for tumor surveillance and genetic counseling in NF1. [Extracted from the article]

A recent study conducted at Cochin Hospital in Paris, France, has identified potential common genetic modifiers of neurofibromas in patients with Neurofibromatosis Type 1 (NF1). Neurofibromas are benign peripheral nerve sheath tumors that can vary greatly in their development. The study found significant associations between certain genetic regions and different types of neurofibromas. The researchers hope that these findings will contribute to the development of personalized care for individuals with NF1 and improve our understanding of the condition. [Extracted from the article]

A recent study conducted in the UK examined the impact of neurofibromatosis type 1 (NF1) with plexiform neurofibromas on the health-related quality of life (HRQoL) and work productivity of adult patients and caregivers. Plexiform neurofibromas are benign nerve-sheath tumors that occur in a significant percentage of NF1 patients. The study found that NF1 PN significantly worsens HRQoL for both adult patients and caregivers compared to the general population, particularly affecting pain and discomfort, anxiety and depression, and caregiver productivity. These findings highlight the need for further research and support for individuals affected by NF1 PN. [Extracted from the article]

A recent report from the Third Affiliated Hospital of Chongqing Medical University in China discusses a case of Neurofibromatosis-Noonan syndrome (NFNS), a rare hereditary disease characterized by symptoms of both neurofibromatosis type 1 (NF1) and Noonan syndrome (NS). The case involves a 12-year-old boy with short stature, cafe-au-lait spots, and various facial abnormalities. Genetic analysis revealed a novel heterozygous variant in the NF1 gene, which is associated with NFNS. The report highlights the uncertainty surrounding the treatment of growth hormone deficiency in NFNS patients and the potential risks of using exogenous growth hormone therapy. [Extracted from the article]

A recent study conducted at the Regional Specialist Hospital in Wroclaw, Poland, has provided new insights into the treatment of cutaneous neurofibromas in patients with neurofibromatosis type 1 (NF1). NF1 is a genetic disorder that affects approximately 2.5 million people worldwide and often leads to the development of benign yet disfiguring cutaneous neurofibromas. The study explored a new approach to removing or reducing these neurofibromas using a minimally invasive and pain-reduced treatment modality. The researchers used a dermatologically focused ultrasound device on seven selected neurofibromas and found that the treatment resulted in full remission in four cases, partial or significant reduction in tumor volume in two cases, and no response in two cases. The researchers concluded that this method shows promise as a safe and minimally invasive treatment for a large number of cutaneous neurofibromas, but further research is needed to refine treatment parameters and enhance response predictability. [Extracted from the article]

Genetics, Health and Medicine, Nervous System Diseases and Conditions, Neurocutaneous Syndromes, Neurodegenerative Diseases and Conditions, Neurofibroma, Neurofibromatoses, Neurofibromatosis, Neurofibromatosis Type 1, Nerve Sheath Neoplasms, Neuromuscular Diseases and Conditions, Peripheral Nervous System Diseases and Conditions, Peripheral Nervous System Neoplasms Keywords: Genetics; Health and Medicine; Nerve Sheath Neoplasms; Nervous System Diseases and Conditions; Neurocutaneous Syndromes; Neurodegenerative Diseases and Conditions; Neurofibroma; Neurofibromatoses; Neurofibromatosis; Neurofibromatosis Type 1; Neuromuscular Diseases and Conditions; Peripheral Nervous System Diseases and Conditions; Peripheral Nervous System Neoplasms EN Genetics Health and Medicine Nerve Sheath Neoplasms Nervous System Diseases and Conditions Neurocutaneous Syndromes Neurodegenerative Diseases and Conditions Neurofibroma Neurofibromatoses Neurofibromatosis Neurofibromatosis Type 1 Neuromuscular Diseases and Conditions Peripheral Nervous System Diseases and Conditions Peripheral Nervous System Neoplasms 2088 2088 1 10/30/23 20231103 NES 231103 2023 NOV 3 (NewsRx) -- By a News Reporter-Staff News Editor at Genomics & Genetics Weekly -- Current study results on neurofibromatosis type 1 have been published. [Extracted from the article]

Keywords: Hunan; People's Republic of China; Asia; Diagnostics and Screening; Genetics; Health and Medicine; Nervous System Diseases and Conditions; Neurocutaneous Syndromes; Neurodegenerative Diseases and Conditions; Neurofibromatoses; Neurofibromatosis; Neurofibromatosis Type 1; Neuromuscular Diseases and Conditions; Peripheral Nervous System Diseases and Conditions; Pseudarthrosis EN Hunan People's Republic of China Asia Diagnostics and Screening Genetics Health and Medicine Nervous System Diseases and Conditions Neurocutaneous Syndromes Neurodegenerative Diseases and Conditions Neurofibromatoses Neurofibromatosis Neurofibromatosis Type 1 Neuromuscular Diseases and Conditions Peripheral Nervous System Diseases and Conditions Pseudarthrosis 454 454 1 10/24/23 20231027 NES 231027 2023 OCT 27 (NewsRx) -- By a News Reporter-Staff News Editor at Genomics & Genetics Weekly -- Current study results on Nervous System Diseases and Conditions - Neurofibromatosis Type 1 have been published. The result showed that nine tissues of 43 non-NF1-CPT patients (21%) had somatic mono-allelic NF1 inactivation, and five of six NF1-CPT patients (83.3%) had bi-allelic NF1 inactivation in tissues. [Extracted from the article]

Keywords: Diagnostics and Screening; Health and Medicine; Nervous System Diseases and Conditions; Neurocutaneous Syndromes; Neurodegenerative Diseases and Conditions; Neurofibromatoses; Neurofibromatosis; Neurofibromatosis Type 1; Neuromuscular Diseases and Conditions; Peripheral Nervous System Diseases and Conditions EN Diagnostics and Screening Health and Medicine Nervous System Diseases and Conditions Neurocutaneous Syndromes Neurodegenerative Diseases and Conditions Neurofibromatoses Neurofibromatosis Neurofibromatosis Type 1 Neuromuscular Diseases and Conditions Peripheral Nervous System Diseases and Conditions 1869 1869 1 10/09/23 20231013 NES 231013 2023 OCT 13 (NewsRx) -- By a News Reporter-Staff News Editor at Genomics & Genetics Weekly -- Investigators publish new report on neurofibromatosis type 1. Study Findings from Mohammed V University Advance Knowledge in Neurofibromatosis Type 1 (A supraclavicular mass with skin macules «cafe-au-lait»: Neurofibromatosis 1) Our news correspondents obtained a quote from the research from Mohammed V University: "The neurofibromatoses are a group of heterogeneous, yet distinct, autosomal-dominant inherited neurogenetic disorders that include neurofibromatosis type 1 (NF1), neurofibromatosis type 2 (NF2), and schwannomatosis. [Extracted from the article]

Keywords: Cells; Cytokine Receptors; Cytokines; Genetics; Health and Medicine; Immunologic Receptors; Intercellular Signaling Peptides and Proteins; Membrane Proteins; Nervous System Diseases and Conditions; Neurofibromatosis Type 1; Neurons EN Cells Cytokine Receptors Cytokines Genetics Health and Medicine Immunologic Receptors Intercellular Signaling Peptides and Proteins Membrane Proteins Nervous System Diseases and Conditions Neurofibromatosis Type 1 Neurons 1214 1214 1 10/03/23 20231006 NES 231006 2023 OCT 6 (NewsRx) -- By a News Reporter-Staff News Editor at Genomics & Genetics Weekly -- A new study on neurofibromatosis type 1 is now available. Cells, Cytokine Receptors, Cytokines, Genetics, Health and Medicine, Immunologic Receptors, Intercellular Signaling Peptides and Proteins, Membrane Proteins, Nervous System Diseases and Conditions, Neurons, Neurofibromatosis Type 1. [Extracted from the article]

Keywords: Genetics; Health and Medicine; Nervous System Diseases and Conditions; Neurofibromatosis Type 1 EN Genetics Health and Medicine Nervous System Diseases and Conditions Neurofibromatosis Type 1 1327 1327 1 09/19/23 20230922 NES 230922 2023 SEP 22 (NewsRx) -- By a News Reporter-Staff News Editor at Genomics & Genetics Weekly -- Researchers detail new data in neurofibromatosis type 1. Keywords for this news article include: University of Pecs, Genetics, Health and Medicine, Neurofibromatosis Type 1, Nervous System Diseases and Conditions. Genetics, Health and Medicine, Nervous System Diseases and Conditions, Neurofibromatosis Type 1. [Extracted from the article]

Genetics, Health and Medicine, Nervous System Diseases and Conditions, Neurocutaneous Syndromes, Neurodegenerative Diseases and Conditions, Neurofibromatoses, Neurofibromatosis, Neurofibromatosis Type 1, Neuromuscular Diseases and Conditions, Peripheral Nervous System Diseases and Conditions, Therapy Keywords: Genetics; Health and Medicine; Nervous System Diseases and Conditions; Neurocutaneous Syndromes; Neurodegenerative Diseases and Conditions; Neurofibromatoses; Neurofibromatosis; Neurofibromatosis Type 1; Neuromuscular Diseases and Conditions; Peripheral Nervous System Diseases and Conditions; Therapy EN Genetics Health and Medicine Nervous System Diseases and Conditions Neurocutaneous Syndromes Neurodegenerative Diseases and Conditions Neurofibromatoses Neurofibromatosis Neurofibromatosis Type 1 Neuromuscular Diseases and Conditions Peripheral Nervous System Diseases and Conditions Therapy 642 642 1 09/11/23 20230915 NES 230915 2023 SEP 15 (NewsRx) -- By a News Reporter-Staff News Editor at Genomics & Genetics Weekly -- Current study results on neurofibromatosis type 1 have been published. [Extracted from the article]

Keywords: Health and Medicine; Nervous System Diseases and Conditions; Neurocutaneous Syndromes; Neurodegenerative Diseases and Conditions; Neurofibromatoses; Neurofibromatosis; Neurofibromatosis Type 1; Neuromuscular Diseases and Conditions; Peripheral Nervous System Diseases and Conditions EN Health and Medicine Nervous System Diseases and Conditions Neurocutaneous Syndromes Neurodegenerative Diseases and Conditions Neurofibromatoses Neurofibromatosis Neurofibromatosis Type 1 Neuromuscular Diseases and Conditions Peripheral Nervous System Diseases and Conditions 1465 1465 1 09/04/23 20230908 NES 230908 2023 SEP 8 (NewsRx) -- By a News Reporter-Staff News Editor at Genomics & Genetics Weekly -- New research on neurofibromatosis type 1 is the subject of a new report. Keywords for this news article include: Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States, North and Central America, Neurofibromatoses, Health and Medicine, Neurocutaneous Syndromes, Neurofibromatosis Type 1, Neuromuscular Diseases and Conditions, Neurodegenerative Diseases and Conditions, Peripheral Nervous System Diseases and Conditions. Health and Medicine, Nervous System Diseases and Conditions, Neurocutaneous Syndromes, Neurodegenerative Diseases and Conditions, Neurofibromatoses, Neurofibromatosis Type 1, Neurofibromatosis, Neuromuscular Diseases and Conditions, Peripheral Nervous System Diseases and Conditions. [Extracted from the article]

Keywords: Hamadan; Iran; Drugs and Therapies; Health and Medicine; Nervous System Diseases and Conditions; Neurocutaneous Syndromes; Neurodegenerative Diseases and Conditions; Neurofibromatoses; Neurofibromatosis; Neurofibromatosis Type 1; Neuromuscular Diseases and Conditions; Peripheral Nervous System Diseases and Conditions EN Hamadan Iran Drugs and Therapies Health and Medicine Nervous System Diseases and Conditions Neurocutaneous Syndromes Neurodegenerative Diseases and Conditions Neurofibromatoses Neurofibromatosis Neurofibromatosis Type 1 Neuromuscular Diseases and Conditions Peripheral Nervous System Diseases and Conditions 662 662 1 09/04/23 20230908 NES 230908 2023 SEP 8 (NewsRx) -- By a News Reporter-Staff News Editor at Genomics & Genetics Weekly -- Data detailed on Nervous System Diseases and Conditions - Neurofibromatosis Type 1 have been presented. Hamadan, Iran, Drugs and Therapies, Health and Medicine, Nervous System Diseases and Conditions, Neurocutaneous Syndromes, Neurodegenerative Diseases and Conditions, Neurofibromatoses, Neurofibromatosis, Neurofibromatosis Type 1, Neuromuscular Diseases and Conditions, Peripheral Nervous System Diseases and Conditions. [Extracted from the article]

Compared to the general population, NF1 patients with cutaneous melanomas had earlier melanoma diagnoses (49.1 vs. 58.6 years, P = 0.012), thicker tumors (3.7 vs. 1.2 mm, P = 0.006), and more frequent disease-specific deaths (27.3% vs. 8.6%, P = 0.005) with shorter survival (12.9 vs. 34.2 months, P = 0.011). Keywords: Cancer; Epidemiology; Health and Medicine; Melanoma; Neoplasms; Nervous System Diseases and Conditions; Neurocutaneous Syndromes; Neurodegenerative Diseases and Conditions; Neurofibromatoses; Neurofibromatosis; Neurofibromatosis Type 1; Neuromuscular Diseases and Conditions; Oncology; Peripheral Nervous System Diseases and Conditions; Risk and Prevention EN Cancer Epidemiology Health and Medicine Melanoma Neoplasms Nervous System Diseases and Conditions Neurocutaneous Syndromes Neurodegenerative Diseases and Conditions Neurofibromatoses Neurofibromatosis Neurofibromatosis Type 1 Neuromuscular Diseases and Conditions Oncology Peripheral Nervous System Diseases and Conditions Risk and Prevention 1509 1509 1 08/28/23 20230901 NES 230901 2023 SEP 1 (NewsRx) -- By a News Reporter-Staff News Editor at Genomics & Genetics Weekly -- Research findings on neurofibromatosis type 1 are discussed in a new report. [Extracted from the article]

Keywords for this news article include: Maebashi, Japan, Asia, Arachnoid, Central Nervous System, Health and Medicine, Hyperplasia, Meninges, Nervous System Diseases and Conditions, Neurocutaneous Syndromes, Neurodegenerative Diseases and Conditions, Neurofibromatoses, Neurofibromatosis, Neurofibromatosis Type 1, Neuromuscular Diseases and Conditions, Peripheral Nervous System Diseases and Conditions, Gunma University. Keywords: Maebashi; Japan; Asia; Arachnoid; Central Nervous System; Health and Medicine; Hyperplasia; Meninges; Nervous System Diseases and Conditions; Neurocutaneous Syndromes; Neurodegenerative Diseases and Conditions; Neurofibromatoses; Neurofibromatosis; Neurofibromatosis Type 1; Neuromuscular Diseases and Conditions; Peripheral Nervous System Diseases and Conditions EN Maebashi Japan Asia Arachnoid Central Nervous System Health and Medicine Hyperplasia Meninges Nervous System Diseases and Conditions Neurocutaneous Syndromes Neurodegenerative Diseases and Conditions Neurofibromatoses Neurofibromatosis Neurofibromatosis Type 1 Neuromuscular Diseases and Conditions Peripheral Nervous System Diseases and Conditions 1357 1357 1 08/14/23 20230818 NES 230818 2023 AUG 18 (NewsRx) -- By a News Reporter-Staff News Editor at Genomics & Genetics Weekly -- Fresh data on Nervous System Diseases and Conditions - Neurofibromatosis Type 1 are presented in a new report. [Extracted from the article]

Keywords: Genetics; Health and Medicine; Nervous System Diseases and Conditions; Neurocutaneous Syndromes; Neurodegenerative Diseases and Conditions; Neurofibromatoses; Neurofibromatosis; Neurofibromatosis Type 1; Neuromuscular Diseases and Conditions; Peripheral Nervous System Diseases and Conditions EN Genetics Health and Medicine Nervous System Diseases and Conditions Neurocutaneous Syndromes Neurodegenerative Diseases and Conditions Neurofibromatoses Neurofibromatosis Neurofibromatosis Type 1 Neuromuscular Diseases and Conditions Peripheral Nervous System Diseases and Conditions 581 581 1 08/07/23 20230811 NES 230811 2023 AUG 11 (NewsRx) -- By a News Reporter-Staff News Editor at Genomics & Genetics Weekly -- Investigators discuss new findings in neurofibromatosis type 1. Genetics, Health and Medicine, Nervous System Diseases and Conditions, Neurocutaneous Syndromes, Neurodegenerative Diseases and Conditions, Neurofibromatoses, Neurofibromatosis, Neurofibromatosis Type 1, Neuromuscular Diseases and Conditions, Peripheral Nervous System Diseases and Conditions. [Extracted from the article]

Keywords for this news article include: Brownsville, Texas, United States, North and Central America, Health and Medicine, Nervous System Diseases and Conditions, Neurocutaneous Syndromes, Neurodegenerative Diseases and Conditions, Neurofibromatoses, Neurofibromatosis, Neurofibromatosis Type 1, Neuromuscular Diseases and Conditions, Peripheral Nervous System Diseases and Conditions, University of Texas Rio Grande Valley. Brownsville, State:Texas, United States, North and Central America, Health and Medicine, Nervous System Diseases and Conditions, Neurocutaneous Syndromes, Neurodegenerative Diseases and Conditions, Neurofibromatoses, Neurofibromatosis, Neurofibromatosis Type 1, Neuromuscular Diseases and Conditions, Peripheral Nervous System Diseases and Conditions Keywords: Brownsville; State:Texas; United States; North and Central America; Health and Medicine; Nervous System Diseases and Conditions; Neurocutaneous Syndromes; Neurodegenerative Diseases and Conditions; Neurofibromatoses; Neurofibromatosis; Neurofibromatosis Type 1; Neuromuscular Diseases and Conditions; Peripheral Nervous System Diseases and Conditions EN Brownsville State:Texas United States North and Central America Health and Medicine Nervous System Diseases and Conditions Neurocutaneous Syndromes Neurodegenerative Diseases and Conditions Neurofibromatoses Neurofibromatosis Neurofibromatosis Type 1 Neuromuscular Diseases and Conditions Peripheral Nervous System Diseases and Conditions 1252 1252 1 08/07/23 20230811 NES 230811 2023 AUG 11 (NewsRx) -- By a News Reporter-Staff News Editor at Genomics & Genetics Weekly -- Researchers detail new data in Nervous System Diseases and Conditions - Neurofibromatosis Type 1. [Extracted from the article]

Keywords: Health and Medicine; Nervous System Diseases and Conditions; Neurocutaneous Syndromes; Neurodegenerative Diseases and Conditions; Neurofibromatoses; Neurofibromatosis; Neurofibromatosis Type 1; Neuromuscular Diseases and Conditions; Pediatrics; Peripheral Nervous System Diseases and Conditions EN Health and Medicine Nervous System Diseases and Conditions Neurocutaneous Syndromes Neurodegenerative Diseases and Conditions Neurofibromatoses Neurofibromatosis Neurofibromatosis Type 1 Neuromuscular Diseases and Conditions Pediatrics Peripheral Nervous System Diseases and Conditions 1192 1192 1 07/31/23 20230731 NES 230731 2023 AUG 4 (NewsRx) -- By a News Reporter-Staff News Editor at Genomics & Genetics Weekly -- New study results on neurofibromatosis type 1 have been published. Keywords for this news article include: Kids Neuroscience Centre, Sydney, Australia, Australia and New Zealand, Pediatrics, Neurofibromatoses, Health and Medicine, Neurocutaneous Syndromes, Neurofibromatosis Type 1, Neuromuscular Diseases and Conditions, Neurodegenerative Diseases and Conditions, Peripheral Nervous System Diseases and Conditions. Health and Medicine, Nervous System Diseases and Conditions, Neurocutaneous Syndromes, Neurodegenerative Diseases and Conditions, Neurofibromatoses, Neurofibromatosis, Neurofibromatosis Type 1, Neuromuscular Diseases and Conditions, Pediatrics, Peripheral Nervous System Diseases and Conditions. [Extracted from the article]

Keywords for this news article include: University of Rwanda, Kigali, Rwanda, Africa, Genetics, Neurofibromatoses, Health and Medicine, Neurocutaneous Syndromes, Neurofibromatosis Type 1, Neuromuscular Diseases and Conditions, Neurodegenerative Diseases and Conditions, Peripheral Nervous System Diseases and Conditions. Keywords: Genetics; Health and Medicine; Nervous System Diseases and Conditions; Neurocutaneous Syndromes; Neurodegenerative Diseases and Conditions; Neurofibromatoses; Neurofibromatosis; Neurofibromatosis Type 1; Neuromuscular Diseases and Conditions; Peripheral Nervous System Diseases and Conditions EN Genetics Health and Medicine Nervous System Diseases and Conditions Neurocutaneous Syndromes Neurodegenerative Diseases and Conditions Neurofibromatoses Neurofibromatosis Neurofibromatosis Type 1 Neuromuscular Diseases and Conditions Peripheral Nervous System Diseases and Conditions 639 639 1 07/24/23 20230728 NES 230728 2023 JUL 28 (NewsRx) -- By a News Reporter-Staff News Editor at Genomics & Genetics Weekly -- Researchers detail new data in neurofibromatosis type 1. Genetics, Health and Medicine, Nervous System Diseases and Conditions, Neurocutaneous Syndromes, Neurodegenerative Diseases and Conditions, Neurofibromatoses, Neurofibromatosis, Neurofibromatosis Type 1, Neuromuscular Diseases and Conditions, Peripheral Nervous System Diseases and Conditions. [Extracted from the article]

Keywords: Enzymes and Coenzymes; Gliomas; Health and Medicine; Kinase; Nervous System Diseases and Conditions; Neurocutaneous Syndromes; Neurodegenerative Diseases and Conditions; Neurofibromatoses; Neurofibromatosis; Neurofibromatosis Type 1; Neuromuscular Diseases and Conditions; Oncology; Peripheral Nervous System Diseases and Conditions; Risk and Prevention EN Enzymes and Coenzymes Gliomas Health and Medicine Kinase Nervous System Diseases and Conditions Neurocutaneous Syndromes Neurodegenerative Diseases and Conditions Neurofibromatoses Neurofibromatosis Neurofibromatosis Type 1 Neuromuscular Diseases and Conditions Oncology Peripheral Nervous System Diseases and Conditions Risk and Prevention 1163 1163 1 07/03/23 20230707 NES 230707 2023 JUL 3 (NewsRx) -- By a News Reporter-Staff News Editor at Genomics & Genetics Weekly -- Researchers detail new data in neurofibromatosis type 1. Enzymes and Coenzymes, Gliomas, Health and Medicine, Kinase, Nervous System Diseases and Conditions, Neurocutaneous Syndromes, Neurodegenerative Diseases and Conditions, Neurofibromatoses, Neurofibromatosis, Neurofibromatosis Type 1, Neuromuscular Diseases and Conditions, Oncology, Peripheral Nervous System Diseases and Conditions, Risk and Prevention. [Extracted from the article]

Keywords: Genetics; Health and Medicine; Nervous System Diseases and Conditions; Neurocutaneous Syndromes; Neurodegenerative Diseases and Conditions; Neurofibromatoses; Neurofibromatosis; Neurofibromatosis Type 1; Neuromuscular Diseases and Conditions; Peripheral Nervous System Diseases and Conditions EN Genetics Health and Medicine Nervous System Diseases and Conditions Neurocutaneous Syndromes Neurodegenerative Diseases and Conditions Neurofibromatoses Neurofibromatosis Neurofibromatosis Type 1 Neuromuscular Diseases and Conditions Peripheral Nervous System Diseases and Conditions 1076 1076 1 05/15/23 20230519 NES 230519 2023 MAY 19 (NewsRx) -- By a News Reporter-Staff News Editor at Genomics & Genetics Weekly -- A new study on neurofibromatosis type 1 is now available. Genetics, Health and Medicine, Nervous System Diseases and Conditions, Neurocutaneous Syndromes, Neurodegenerative Diseases and Conditions, Neurofibromatoses, Neurofibromatosis, Neurofibromatosis Type 1, Neuromuscular Diseases and Conditions, Peripheral Nervous System Diseases and Conditions. [Extracted from the article]

Genetics, Health and Medicine, Nervous System Diseases and Conditions, Neurocutaneous Syndromes, Neurodegenerative Diseases and Conditions, Neurofibromatoses, Neurofibromatosis, Neurofibromatosis Type 1, Neuromuscular Diseases and Conditions, Peripheral Nervous System Diseases and Conditions Keywords: Genetics; Health and Medicine; Nervous System Diseases and Conditions; Neurocutaneous Syndromes; Neurodegenerative Diseases and Conditions; Neurofibromatoses; Neurofibromatosis; Neurofibromatosis Type 1; Neuromuscular Diseases and Conditions; Peripheral Nervous System Diseases and Conditions EN Genetics Health and Medicine Nervous System Diseases and Conditions Neurocutaneous Syndromes Neurodegenerative Diseases and Conditions Neurofibromatoses Neurofibromatosis Neurofibromatosis Type 1 Neuromuscular Diseases and Conditions Peripheral Nervous System Diseases and Conditions 1199 1199 1 05/08/23 20230512 NES 230512 2023 MAY 12 (NewsRx) -- By a News Reporter-Staff News Editor at Genomics & Genetics Weekly -- Fresh data on neurofibromatosis type 1 are presented in a new report. [Extracted from the article]

Genetics, Health and Medicine, Nervous System Diseases and Conditions, Neurocutaneous Syndromes, Neurodegenerative Diseases and Conditions, Neurofibromatoses, Neurofibromatosis, Neurofibromatosis Type 1, Neuromuscular Diseases and Conditions, Pediatrics, Peripheral Nervous System Diseases and Conditions, Risk and Prevention Keywords: Genetics; Health and Medicine; Nervous System Diseases and Conditions; Neurocutaneous Syndromes; Neurodegenerative Diseases and Conditions; Neurofibromatoses; Neurofibromatosis; Neurofibromatosis Type 1; Neuromuscular Diseases and Conditions; Pediatrics; Peripheral Nervous System Diseases and Conditions; Risk and Prevention EN Genetics Health and Medicine Nervous System Diseases and Conditions Neurocutaneous Syndromes Neurodegenerative Diseases and Conditions Neurofibromatoses Neurofibromatosis Neurofibromatosis Type 1 Neuromuscular Diseases and Conditions Pediatrics Peripheral Nervous System Diseases and Conditions Risk and Prevention 1048 1048 1 04/10/23 20230414 NES 230414 2023 APR 14 (NewsRx) -- By a News Reporter-Staff News Editor at Genomics & Genetics Weekly -- Current study results on neurofibromatosis type 1 have been published. [Extracted from the article]

Keywords: Health and Medicine; Nervous System Diseases and Conditions; Neurocutaneous Syndromes; Neurodegenerative Diseases and Conditions; Neurofibromatoses; Neurofibromatosis; Neurofibromatosis Type 1; Neuromuscular Diseases and Conditions; Pediatrics; Peripheral Nervous System Diseases and Conditions EN Health and Medicine Nervous System Diseases and Conditions Neurocutaneous Syndromes Neurodegenerative Diseases and Conditions Neurofibromatoses Neurofibromatosis Neurofibromatosis Type 1 Neuromuscular Diseases and Conditions Pediatrics Peripheral Nervous System Diseases and Conditions 1083 1083 1 04/10/23 20230414 NES 230414 2023 APR 14 (NewsRx) -- By a News Reporter-Staff News Editor at Genomics & Genetics Weekly -- New study results on neurofibromatosis type 1 have been published. Health and Medicine, Nervous System Diseases and Conditions, Neurocutaneous Syndromes, Neurodegenerative Diseases and Conditions, Neurofibromatoses, Neurofibromatosis, Neuromuscular Diseases and Conditions, Pediatrics, Peripheral Nervous System Diseases and Conditions, Neurofibromatosis Type 1. [Extracted from the article]

Keywords: Rotterdam; Netherlands; Europe; Diagnostics and Screening; Genetics; Health and Medicine; Nervous System Diseases and Conditions; Neurocutaneous Syndromes; Neurodegenerative Diseases and Conditions; Neurofibromatoses; Neurofibromatosis; Neurofibromatosis Type 1; Neuromuscular Diseases and Conditions; Peripheral Nervous System Diseases and Conditions; Protein Expression; Proteomics EN Rotterdam Netherlands Europe Diagnostics and Screening Genetics Health and Medicine Nervous System Diseases and Conditions Neurocutaneous Syndromes Neurodegenerative Diseases and Conditions Neurofibromatoses Neurofibromatosis Neurofibromatosis Type 1 Neuromuscular Diseases and Conditions Peripheral Nervous System Diseases and Conditions Protein Expression Proteomics 971 971 1 04/03/23 20230407 NES 230407 2023 APR 7 (NewsRx) -- By a News Reporter-Staff News Editor at Genomics & Genetics Weekly -- A new study on Nervous System Diseases and Conditions - Neurofibromatosis Type 1 is now available. Rotterdam, Netherlands, Europe, Diagnostics and Screening, Genetics, Health and Medicine, Nervous System Diseases and Conditions, Neurocutaneous Syndromes, Neurodegenerative Diseases and Conditions, Neurofibromatoses, Neurofibromatosis, Neurofibromatosis Type 1, Neuromuscular Diseases and Conditions, Peripheral Nervous System Diseases and Conditions, Proteomics, Protein Expression. [Extracted from the article]

Keywords: Lebanon; State:New Hampshire; United States; North and Central America; Health and Medicine; Nervous System Diseases and Conditions; Neurocutaneous Syndromes; Neurodegenerative Diseases and Conditions; Neurofibromatoses; Neurofibromatosis; Neurofibromatosis Type 1; Neuromuscular Diseases and Conditions; Peripheral Nervous System Diseases and Conditions EN Lebanon State:New Hampshire United States North and Central America Health and Medicine Nervous System Diseases and Conditions Neurocutaneous Syndromes Neurodegenerative Diseases and Conditions Neurofibromatoses Neurofibromatosis Neurofibromatosis Type 1 Neuromuscular Diseases and Conditions Peripheral Nervous System Diseases and Conditions 1194 1194 1 03/23/23 20230324 NES 230324 2023 MAR 24 (NewsRx) -- By a News Reporter-Staff News Editor at Genomics & Genetics Weekly -- A new study on Nervous System Diseases and Conditions - Neurofibromatosis Type 1 is now available. Lebanon, State:New Hampshire, United States, North and Central America, Health and Medicine, Nervous System Diseases and Conditions, Neurocutaneous Syndromes, Neurodegenerative Diseases and Conditions, Neurofibromatoses, Neurofibromatosis, Neurofibromatosis Type 1, Neuromuscular Diseases and Conditions, Peripheral Nervous System Diseases and Conditions. [Extracted from the article]